Immuneering CORP 10-Q quarterly reports

Immuneering Corporation reported progress in its atebimetinib clinical trials, including positive interim data, while also detailing increased operating expenses and a continued net loss.

Immuneering Corporation filed its Form 10-Q for the quarter ended March 31, 2026, detailing its financial performance, ongoing clinical trials, and strategic outlook.

Immuneering Corporation reported a significant increase in cash reserves to $227.6 million, extending its runway into 2029, and announced positive interim survival data for its lead pancreatic cancer drug candidate, atebimetinib.

Immuneering Corporation's Q2 2025 filing highlights promising interim clinical data for atebimetinib in pancreatic cancer, despite ongoing financial challenges and a going concern warning.

Immuneering Corporation's Q1 2025 results show continued losses and raise substantial doubt about its ability to continue as a going concern.

Immuneering Corporation's Q3 2024 report highlights ongoing clinical trials for IMM-1-104 and IMM-6-415, with a focus on financial stability and future funding needs.

Immuneering Corporation's second quarter 2024 results show a net loss of $14.1 million, with ongoing clinical trials for IMM-1-104 and IMM-6-415 progressing.

Immuneering Corporation announced its first quarter 2024 financial results, highlighting progress in its clinical trials for IMM-1-104 and IMM-6-415.